Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells.

Wong J, Choi SYC, Liu R, Xu E, Killam J, Gout PW, Wang Y.

Front Cell Infect Microbiol. 2019 Feb 12;9:25. doi: 10.3389/fcimb.2019.00025. eCollection 2019.

2.

Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y.

Front Genet. 2018 Jul 4;9:232. doi: 10.3389/fgene.2018.00232. eCollection 2018. Review.

3.

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.

Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1587. [Epub ahead of print]

4.

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.

Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.

5.

Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.

Cancer Res. 2018 May 15;78(10):2691-2704. doi: 10.1158/0008-5472.CAN-17-3677. Epub 2018 Feb 27.

6.

Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.

Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y.

Int J Cancer. 2018 Jul 15;143(2):419-429. doi: 10.1002/ijc.31310. Epub 2018 Mar 1.

7.

Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.

Qu S, Ci X, Xue H, Dong X, Hao J, Lin D, Clermont PL, Wu R, Collins CC, Gout PW, Wang Y.

Br J Cancer. 2018 Mar 20;118(6):802-812. doi: 10.1038/bjc.2017.474. Epub 2018 Jan 30.

8.

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.

Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y.

Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237.

9.

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC.

Eur Urol. 2018 Apr;73(4):524-532. doi: 10.1016/j.eururo.2017.02.038. Epub 2017 Mar 19.

10.

BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.

Luk IS, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2017 Mar 15;23(6):1542-1551. doi: 10.1158/1078-0432.CCR-16-0718. Epub 2016 Sep 23.

11.

Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers.

Sun X, Clermont PL, Jiao W, Helgason CD, Gout PW, Wang Y, Qu S.

Int J Cancer. 2016 Aug 15;139(4):899-907. doi: 10.1002/ijc.30133. Epub 2016 Apr 21.

12.

The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.

Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2016 Jun 1;22(11):2721-33. doi: 10.1158/1078-0432.CCR-15-1624. Epub 2016 Jan 11.

13.

Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence.

Hao J, Chiang YT, Gout PW, Wang Y.

Front Biosci (Schol Ed). 2016 Jan 1;8:44-55.

PMID:
26709895
14.

Subrenal capsule grafting technology in human cancer modeling and translational cancer research.

Wang Y, Wang JX, Xue H, Lin D, Dong X, Gout PW, Gao X, Pang J.

Differentiation. 2016 Apr-Jun;91(4-5):15-9. doi: 10.1016/j.diff.2015.10.012. Epub 2015 Nov 4. Review.

PMID:
26547391
15.

Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.

Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.

Oncotarget. 2015 Jan 30;6(3):1806-20.

16.

Lessons from patient-derived xenografts for better in vitro modeling of human cancer.

Choi SY, Lin D, Gout PW, Collins CC, Xu Y, Wang Y.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:222-37. doi: 10.1016/j.addr.2014.09.009. Epub 2014 Oct 13. Review.

17.

The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.

Luk SU, Xue H, Cheng H, Lin D, Gout PW, Fazli L, Collins CC, Gleave ME, Wang Y.

Oncotarget. 2014 Aug 30;5(16):6896-908.

18.

Next generation patient-derived prostate cancer xenograft models.

Lin D, Xue H, Wang Y, Wu R, Watahiki A, Dong X, Cheng H, Wyatt AW, Collins CC, Gout PW, Wang Y.

Asian J Androl. 2014 May-Jun;16(3):407-12. doi: 10.4103/1008-682X.125394. No abstract available.

19.

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification.

Chiang YT, Gout PW, Collins CC, Wang Y.

Asian J Androl. 2014 Jul-Aug;16(4):545-8. doi: 10.4103/1008-682X.122875.

20.

GATA2 as a potential metastasis-driving gene in prostate cancer.

Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y.

Oncotarget. 2014 Jan 30;5(2):451-61.

21.

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.

Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC, Wang Y.

Mol Oncol. 2014 Mar;8(2):311-22. doi: 10.1016/j.molonc.2013.12.004. Epub 2013 Dec 15.

22.

High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.

Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Coll A, Fazli L, Sharma M, Beltran H, Rubin M, Cox M, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang Y.

Cancer Res. 2014 Feb 15;74(4):1272-83. doi: 10.1158/0008-5472.CAN-13-2921-T. Epub 2013 Dec 19.

23.

Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?

Choi SY, Collins CC, Gout PW, Wang Y.

J Pathol. 2013 Aug;230(4):350-5. doi: 10.1002/path.4218. Review.

24.

BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells.

Low CG, Luk IS, Lin D, Fazli L, Yang K, Xu Y, Gleave M, Gout PW, Wang Y.

PLoS One. 2013;8(2):e55837. doi: 10.1371/journal.pone.0055837. Epub 2013 Feb 8.

25.

Lessons from in-vivo models of castration-resistant prostate cancer.

Lin D, Gout PW, Wang Y.

Curr Opin Urol. 2013 May;23(3):214-9. doi: 10.1097/MOU.0b013e32835e9f07.

PMID:
23385975
26.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

27.

The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P.

Antioxid Redox Signal. 2013 Feb 10;18(5):522-55. doi: 10.1089/ars.2011.4391. Epub 2012 Aug 3. Review.

28.

Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers.

Choi SY, Gout PW, Collins CC, Wang Y.

Differentiation. 2012 Jun;83(5):293-8. doi: 10.1016/j.diff.2012.02.005. Epub 2012 Apr 1. Review.

PMID:
22472059
29.

Drug sensitivity testing for personalized lung cancer therapy.

Gout PW, Wang Y.

J Thorac Dis. 2012 Feb;4(1):17-8. doi: 10.3978/j.issn.2072-1439.2011.06.07. No abstract available.

30.

Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, Bertino JR, Lubin M, Wang Y.

Mol Cancer Ther. 2012 Mar;11(3):775-83. doi: 10.1158/1535-7163.MCT-11-0826. Epub 2012 Jan 17.

31.

MicroRNAs associated with metastatic prostate cancer.

Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW, Wang Y.

PLoS One. 2011;6(9):e24950. doi: 10.1371/journal.pone.0024950. Epub 2011 Sep 30.

32.

Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.

Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ.

PLoS One. 2011;6(7):e21121. doi: 10.1371/journal.pone.0021121. Epub 2011 Jul 6.

33.

Use of irinotecan for treatment of small cell carcinoma of the prostate.

Tung WL, Wang Y, Gout PW, Liu DM, Gleave M, Wang Y.

Prostate. 2011 May 15;71(7):675-81. doi: 10.1002/pros.21283. Epub 2010 Oct 14.

PMID:
20949523
34.
35.

Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor.

Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire JA, Wang Y.

Prostate. 2010 Nov 1;70(15):1636-44. doi: 10.1002/pros.21199.

PMID:
20564316
36.

Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.

Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S, Wang Y.

Clin Cancer Res. 2010 Mar 1;16(5):1442-51. doi: 10.1158/1078-0432.CCR-09-2878. Epub 2010 Feb 23.

37.

Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.

Pham AN, Blower PE, Alvarado O, Ravula R, Gout PW, Huang Y.

J Pharmacol Exp Ther. 2010 Mar;332(3):949-58. doi: 10.1124/jpet.109.162248. Epub 2009 Dec 9.

PMID:
20007406
38.

The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.

Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, Wang YZ.

Cancer Chemother Pharmacol. 2009 Aug;64(3):463-72. doi: 10.1007/s00280-008-0894-4. Epub 2008 Dec 24.

PMID:
19104813
39.

The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance.

Lo M, Ling V, Wang YZ, Gout PW.

Br J Cancer. 2008 Aug 5;99(3):464-72. doi: 10.1038/sj.bjc.6604485. Epub 2008 Jul 22.

40.

ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.

Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA, Wang YZ.

Cancer Res. 2008 Jun 1;68(11):4352-9. doi: 10.1158/0008-5472.CAN-07-5237.

41.

The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.

Lo M, Wang YZ, Gout PW.

J Cell Physiol. 2008 Jun;215(3):593-602. doi: 10.1002/jcp.21366. Review.

PMID:
18181196
42.

Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin.

Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR.

Chemotherapy. 2007;53(3):210-7. Epub 2007 Mar 15.

PMID:
17356269
43.

Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy.

Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ.

Prostate. 2007 Feb 1;67(2):162-71.

PMID:
17075799
44.

Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.

Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ.

Clin Cancer Res. 2006 Jul 1;12(13):4043-54.

45.

Animal models for growth hormone gene therapy.

Peroni CN, Gout PW, Bartolini P.

Curr Gene Ther. 2005 Oct;5(5):493-509. Review.

PMID:
16250890
46.

An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line.

Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ.

Lab Invest. 2005 Nov;85(11):1392-404.

47.

Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.

Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ.

Gynecol Oncol. 2005 Jan;96(1):48-55.

PMID:
15589579
48.

Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells.

Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR.

Anticancer Res. 2003 Nov-Dec;23(6C):4571-9.

PMID:
14981898
49.

Synthesis and chromatographic purification of recombinant human pituitary hormones.

Ribela MT, Gout PW, Bartolini P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jun 25;790(1-2):285-316. Review.

PMID:
12767339
50.

Current and prospective applications of metal ion-protein binding.

Ueda EK, Gout PW, Morganti L.

J Chromatogr A. 2003 Feb 21;988(1):1-23. Review.

PMID:
12647817

Supplemental Content

Support Center